Back to top
more

Akoya Biosciences (AKYA)

(Delayed Data from NSDQ)

$2.88 USD

2.88
466,237

-0.03 (-1.03%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $2.90 +0.02 (0.69%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for AKYA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Akoya Biosciences, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 83 81 113 17 22
Receivables 17 10 9 6 13
Notes Receivable 0 0 0 0 0
Inventories 18 14 9 4 4
Other Current Assets 4 7 9 1 2
Total Current Assets 122 112 141 29 41
Net Property & Equipment 11 10 7 6 5
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 1 2 3 1 0
Deferred Charges 0 0 0 0 0
Intangibles 36 38 39 41 42
Deposits & Other Assets 1 1 1 1 1
Total Assets 180 176 191 78 89
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 12 11 9 5 8
Current Portion Long-Term Debt 0 0 0 1 0
Current Portion Capital Leases 1 1 0 0 0
Accrued Expenses 13 17 13 7 9
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 7 6 4 4 4
Total Current Liabilities 35 37 28 17 21
Mortgages 0 0 0 0 0
Deferred Taxes/Income 3 2 1 1 1
Convertible Debt 0 0 0 0 0
Long-Term Debt 75 63 32 33 24
Non-Current Capital Leases 1 1 0 0 0
Other Non-Current Liabilities 6 6 8 7 8
Minority Interest (Liabilities) 0 0 0 69 64
Total Liabilities 127 117 70 129 120
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 1 1
Common Stock (Par) 0 0 0 0 0
Capital Surplus 284 225 217 0 0
Retained Earnings -230 -167 -96 -52 -31
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 54 59 121 -51 -30
Total Liabilities & Shareholder's Equity 180 176 191 78 89
Total Common Equity 54 59 121 -52 -31
Shares Outstanding 49.00 37.90 37.20 NA NA
Book Value Per Share 1.10 1.55 3.26 0.00 0.00

Fiscal Year End for Akoya Biosciences, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 45 62 83 79 93
Receivables 17 13 17 16 13
Notes Receivable 0 0 0 0 0
Inventories 25 23 18 19 16
Other Current Assets 3 4 4 4 4
Total Current Assets 90 102 122 117 126
Net Property & Equipment 8 9 11 11 11
Investments & Advances 4 0 0 0 0
Other Non-Current Assets 1 1 1 1 2
Deferred Charges 0 0 0 0 0
Intangibles 34 35 36 36 37
Deposits & Other Assets 1 1 1 1 1
Total Assets 144 155 180 177 189
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 10 11 12 12 12
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 1 1 1 1 1
Accrued Expenses 13 12 13 13 15
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 6 7 7 7 7
Total Current Liabilities 33 33 35 36 37
Mortgages 0 0 0 0 0
Deferred Taxes/Income 3 3 3 3 3
Convertible Debt 0 0 0 0 0
Long-Term Debt 76 75 75 64 64
Non-Current Capital Leases 1 1 1 1 1
Other Non-Current Liabilities 4 6 5 5
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 122 122 127 115 117
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 289 286 284 281 278
Retained Earnings -267 -254 -230 -219 -206
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 22 33 54 62 72
Total Liabilities & Shareholder's Equity 144 155 180 177 189
Total Common Equity 22 33 54 62 72
Shares Outstanding 49.30 49.30 49.00 48.90 38.40
Book Value Per Share 0.45 0.66 1.10 1.27 1.87